Exudative Age-Related Macular Degeneration

Home Monitoring in eAMD Treatment

Retrospective Multicenter Real-world Observational Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration

An Assistant Model for Anti-VEGF Therapy Decision

Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration

Ethical Issues of Using Gene Therapy in the Treatment of AMD

A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration

A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration

Efficacy and Safety of Intravitreal Conbercept With Modified Treat-and-Extend Regimens in Exudative AMD

Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept

X-82 to Treat Age-related Macular Degeneration

Stem Cell Therapy for Outer Retinal Degenerations

Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab

Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy

Intravitreal Aflibercept for Submacular Hemorrhage

Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD

ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)

LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration

Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD

Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab

Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy